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Youth Living with HIV/AIDS (YLWHIV) have a higher risk of developing immunodeficiency
related illnesses including certain cancers than their general population counterparts
of the same age. This narrative review of current available literature describes factors
associated with pediatric access to oncological services, and the role economic
strengthening could play in improving health outcomes for this vulnerable population.
Findings suggest that both HIV-infected and -uninfected children living in low and
middle-income countries struggle with access and adherence to cancer treatment and
care. Cost of treatment is a major barrier to access and adherence. Asset-building
savings programs may increase financial security and subsequently result in better health
outcomes although they have not been utilized to improve access to cancer treatment.
Keywords: HIV/AIDS, malignancies, youth, sub-Saharan Africa, access to cancer services, economic
strengthening
INTRODUCTION
The HIV/AIDS pandemic continues to pose a significant threat to global public health (1).
According to theWorldHealthOrganization (WHO),∼37.9million people were living withHIV at
the end of 2018, with 1.7 million new infections within that year globally (2). Furthermore, 940,000
people died from HIV-related causes globally in 2017 (2). Africa is the most affected region, with
more than two thirds of the total new HIV infections and people living with HIV worldwide (2, 3).
Youth (0–24 years) are greatly affected by the HIV pandemic. This can be explained by their
diverse risk factors whereby children can acquire HIV from their infected mothers during birth
and postnatally from breast feeding while 15 to 24-year-olds fall within a young adult category for
which unsafe sex is the main risk factor for HIV contraction (4, 5). In both 2016 and 2018, youth
aged 13–24 made up 21% of all new HIV diagnoses in the United States (U.S.) (6, 7). Additionally,
WHO global health estimates from 2016 show that for females aged 10–14 years, HIV/AIDS was
the leading cause of mortality while for their male counterparts, HIV/AIDS was the leading cause of
infection-related death and third leading cause of death overall (after road injuries and drowning)
(6). Furthermore, for youth living with HIV (YLWHIV); defined as youth under the age of 18 years,
AIDS-related illnesses are still among the leading causes of mortality (6). Africa is home to most of
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the affected children whereby 58% (1.04 million) are from
Eastern and Southern Africa and 29% (0.5 million) are from
Western and Central Africa (8).
AIDS-related illnesses contributing tomortality among people
living with HIV are thought to develop as a result of HIV effects
on patients’ immune systems (9). Examples of these illnesses
are opportunistic coinfections (e.g., tuberculosis, toxoplasmosis,
pneumocystis pneumonia) and some cancers (10). Regarding the
latter, people living with HIV have a significantly higher risk
of developing certain cancers than the general population of
the same age (11). HIV infection among cancer patients is also
associated with a significantly higher risk of dying from that
cancer (11).
HIV-associated cancer risk and survival among YLWHIV has
changed over time with the advent of increased access to and
uptake of antiretroviral therapy (ART) (8). Prior to ART, cancer
risks were reported at >40-fold higher in HIV positive youth (1),
with the greatest risks for Kaposi’s sarcoma (KS), Non-Hodgkin’s
lymphoma, and Burkitt’s lymphoma (12–15). In the post-ART
era, 4 to 14-fold higher pediatric cancer risks have been reported
in South Africa (8, 16). It is important to highlight that despite the
increased access and effectiveness of ART among people living
withHIV, cancer survival among YLWHIV is low in low-resource
settings and cancer risk is still higher for children that start ART
at an older age and/or who have greater immunosuppression than
for those who start ART a younger age and/or who have less
immunosuppression (16).
The WHO highlights the importance of early diagnosis for
all pediatric cancers and access to treatment for children and
adolescents with cancer for better survival (17). Proper access
to quality care can result in better prognosis (18). Evidence
from high income countries indicates that with proper access to
quality care, more than 80% of children with cancer can survive
and live full and healthy lives (19–21). This paper provides a
narrative review of the factors associated with youth pediatric
access to oncological services; and the potential role of economic
strengthening can play in improving health outcomes for this
population and for all children in low resource settings.
METHODS
This narrative review has the two primary objectives (1)
examining access to oncological treatment services among
children and (2) discussing the potential role of economic
strengthening programs in improving health outcomes for
YLWHIV who develop cancers.
Search Strategy
Articles were obtained through a comprehensive search of
MEDLINE, CINAHL, CINAHL Plus, Ovid, PsycINFO, Academic
Search Complete, Global Health, SocINDEX, SOCIndex with
Full Text, and EBSCOhost’s Clinical and Academic Collections
using search terms in Table 1. This search was carried out and
reviewed for eligibility by two research assistants. These articles
were supplemented through Google scholar and references from
key articles.
Inclusion/Exclusion Criteria
Out of more than 100 articles and internet sources identified
from the search conducted over a period of ∼4 months,
material from 73 sources that provided information related to
the papers’ objectives was included. These articles include those
obtained during the search (43) and supplemented sources (30)
obtained from Google scholar searches and reference lists from
included articles.
Global Burden of Cancers Among Youth Living With
HIV
While most YLWHIV live in SSA, cancer studies from this region
are scarce. The number of YLWHIV who develop a malignancy
in SSA is poorly defined and available data generally focuses on
younger children (<16 years). HIV-related cancer surveillance
is further hampered by lack of systematic collection of cancer
diagnoses in HIV cohorts and absence of HIV status in available
local cancer registries.
Of an estimated 429,000 expected new cases of childhood
cancer each year, almost 90% will occur in LMICs and over 80%
of the global burden of pediatric cancer mortality is in LMIC
(22, 23). A review of the literature demonstrated that the burden
of cancers and cancer types differs greatly between high income
countries and low- to lower-middle-income countries (LMICs)
(22, 24) as well as by region (24–26). Additionally, Ward et al.
estimated that over 3 million cases of pediatric cancer will go
undiagnosed between 2015 and 2030 (22) and 56% of cases in
East Africa will be undiagnosed compared to only 3% in North
America (22).
Studies from lower income countries in the pre-ART
era demonstrated a >40-fold higher risk of developing
cancer in HIV-infected youth compared to their general
population counterparts, with Kaposi sarcoma (KS), Non-
Hodgkin’s lymphoma and specifically Burkitt’s lymphoma having
the greatest relative risks (12–15). While the introduction of
and increased access to ART increased survival, studies from
South Africa in the post-ART era still find a higher risk (between
14 and 14 times) of developing cancer among YLWHIV (8,
16). Additionally, a retrospective study in South Africa found
that HIV-positive children with cancer were generally younger
(average age 6 years) compared to HIV-negative patients with
cancer (average age 6.5 years) (25, 27). This study also reported
higher mortality among HIV-positive children and that the ratio
of living children who were cancer-free to the total of children
in the respective category, was significantly smaller among HIV-
positive participants. Studies from Malawi on Kaposi sarcoma
reported that YLWHIV in the post-ART era are still at a high risk
for the disease (28, 29).
Access to Oncological Treatment Services for Youth
YLWHIV generally have poor survival despite chemotherapy
compared to uninfected peers, mainly due to patients’ severe
immunodeficiency (21, 30). However, survival may bemoderated
by differences in access to therapeutic options between HIV-
positive and HIV-negative children with cancer. Proper access to
quality care can result in better prognosis as well as minimal side
or late effects associated with disease and treatment, respectively,
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TABLE 1 | Search terms and key words used in the literature search.
Youth terms HIV/AIDS terms Cancer terms Treatment/Treatment delay terms Epidemiology terms
Pediatric
Pediatrics
Pediatric*
Children
Kids Adolescents Youth
Kid
Adolescent Childhood
Young adults—people teens
and people in early twenties
Teens
Youngster
Boy
Girl
Infant
HIV
AIDS
Human immunodeficiency virus
Acquired immunodeficiency
syndrome
Persons living with HIV
Persons living with AIDS
People living with HIV
People living with AIDS
Persons living with HIV/AIDS
People living with HIV/AIDS
Viral suppression
Virally suppressed
*HAART
*ART
*Pediatric ART
cART
Cancer
Cancers
Malignancies
Malignant
Malignancy
Tumor
Tumors
Neoplasm
Neoplasms
Carcinoma
Carcinomas
Oncology
Malignant tumors
Kaposi sarcoma
Non-Hodgkin’s lymphoma
Burkitt’s lymphoma
Leiomyosarcoma
Cervical cancer
Lymphoma
HPV-related cancers
HIV-related cancers
Lymphoproliferative disorder*
Cancer treat*
Cancer therap*
Chemotherap*
Surger*
Oncology services radiation adj3 therap*
Delay* in Cancer treat*
Delay* adj3 cancer diagnosis
Delay* in Cancer therap*
Delay* adj3 chemotherap*
Delay* adj3 Oncology services
Abandon* adj3 Cancer treat*
Access* adj3 Cancer treat*
Access* adj3 Cancer therap*
Access* adj3 chemotherap*
Access* adj3 Oncology services
Abandonment Care Pathways
Systems infrastructure
Epidemiology
Incidence
Cumulative incidence
Prevalence
Survival analysis
Survival rates
Kaplan Meier
Incidence rates
Risk ratio
Relative risk
Rate ratio
Incidence density
Prevalence ratio
Standardized incidence rate
whereby younger YLWHIV who access care earlier and at lower
levels of immunosuppression may have better tolerance and/or
responses to necessary high doses of chemotherapy (18, 31).
Evidence from high income countries indicates that with proper
access to quality care, more than 80% of children with cancer
can survive and live full and healthy lives (32). A study in South
Africa indicated that YLWHIV receiving antiretroviral therapy
(ART) have a substantially lower risk of developing cancer than
those who are not on ART [hazard ratio (HR) 0.29] (16). Biggar
et al. also found that survival among YLWHIV with cancer
was greater for those treated with ART and chemotherapy (33).
Yet, numerous children (both HIV-infected and uninfected) in
LMICs continue to struggle with access and adherence to care,
contributing to childhood cancer deaths in low resource settings
globally (17). Hence, timely access to quality healthcare is an
important public health concern.
Access to pediatric oncology services is defined in terms
of delay, waiting time, as well as treatment adherence and
abandonment. Delay is further categorized as patient/parent
delay, health care system delay, physician/health system delay,
referral delay, diagnosis delay, treatment delay, lag time, and
ultimately, total delay (defined as the time from onset of
symptoms to initiation of therapy) (18, 34). Total delay in
childhood cancer is a major contributor to cancer-related death
among children worldwide and many factors contribute to this
delay (34, 35). Overall, health system–related factors have been
found to contribute more significantly to lag time than parent
delays (33, 34, 36).
Factors Associated With Delay and Abandonment
Among Youth Living in LMICs
Several barriers exist to accessing cancer treatment among
children and consequently contribute to delay (see Figure 1).
As children typically depend on parents/guardians to access
health services, individual-level factors are grouped along with
interpersonal factors since their influence is ultimately evaluated
on an interpersonal basis. Regarding structural factors, most
LMICs have only few established cancer centers, whereby cancer
services are usually obtained from general surgical or medical
departments in non-specialized hospitals (37). These are district
or regional hospitals, with little or no information about quantity
or quality of the services provided (37). They also typically
exist in large urban areas, whereas most of the population
lives in rural areas. These hospitals often lack reliable routine
pathology, imaging, oncology nursing, and specialized pharmacy
departments or have units that offer low quality service and
insufficiently trained personnel. This lack or limited scope of
pathology services is a major challenge in several SSA countries
where there is typically one pathologist for every 500,000 to 1
million people (37).
Lack of affordable local treatments options are amplified by
long distances to treatment centers and transportation difficulties
(38, 39). Clinical care and transportation costs also play major
roles in patient delay. In both Uganda and western Kenya,
nearly all guardians rely on public transportation to reach the
cancer referral centers, yet transportation costs are high and
travel time is long (40). Lack of funds is a critical factor for
treatment abandonment (38, 40). Furthermore, the search for an
accurate diagnosis and effective treatment was resource-intensive
and complicated for many guardians and generally involved
multiple visits to different health facilities and care providers (40).
Unfortunately, many children remained undiagnosed or were
inappropriately treated before getting to cancer referral centers.
Studies highlight mismanagement of cancer cases at lower
level facilities as a key weakness in health care systems which
contributes to late stage of presentation and poor outcomes
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FIGURE 1 | Factors associated with total delay and abandonment of cancer care among children and youth in LMICs.
among children (40). Relatedly, parents who sought alternative
sources of care had perceptions of unsatisfactory management by
respective health facilities and a lack of confidence in health care
systems (39). Alternative treatments were also sought due to the
cost of modern medicine and the belief that alternative medicine
had fewer side effects (41).
Caregiver education and profession also affect access to cancer
treatment services. In a study in Argentina, retinoblastoma
patients whose parents had an elementary education or lower had
a greater risk of longer patient delay [odds ratio (OR) = 6.34]
(18). In Mexico, children whose parents had the lowest level of
education had longer delays in diagnosis (OR = 1.4 for fathers
and 1.5 for mothers).While there were no significant associations
with father’s profession, the lag time for mothers with a “blue
collar” profession was greater than for both housewives or
mothers with academic professions (8.5–13.5 weeks vs. 5.5–6
weeks) (42). Conversely, in Nigeria, children of parents with
a higher level of education, who favor private hospitals over
public ones, suffered longer diagnosis delays despite being more
economically empowered (43).
In a study conducted in Latin America, Asia and the
Caribbean, household assets correlated with adherence to care
(41). In Uganda, household dynamics (e.g., distribution of
family tasks, guardian’s role as caretaker, and social support)
contributed to patient/parent delay whereby seeking treatment
created a deficit in the day-to-day running of households
(40). Consequently, parents without a support system for other
children in the home and/or someone to take over their tasks
had longer delay. Parent delay among Ugandan guardians was
also influenced by guardians’ beliefs about the curability of
cancer, health system delay, and by guardians’ perceptions of
cancer as a contagious disease (41). Hence, understanding the
role of cultural/community context when describing barriers and
designing interventions is essential.
A study in Israel, a high-income country, also observed a
significant positive correlation between child’s age at diagnosis
and lag time whereby the lag time increased as the child’s
age increased (44). Diagnosis delay was shortest for children
between the ages of 0–2 years despite no significant differences
in histopathology, grade or location of tumors, and parental
persistence (number of consultations before diagnosis) across
age groups. The association with child’s age was explained
by the expectation that younger children have closer parental
supervision, which may facilitate the recognition of symptoms
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and signs, as opposed to older children and adolescents whomore
often initiate the recognition of signs and symptoms themselves.
Adolescents may also be more likely to undervalue symptoms
and delay calling attention to them, resulting in increased delays.
Moreover, if the child was the oldest, the parent’s delay was
shorter, underlying birth order as a critical factor. Patients with
younger mothers were more likely to seek treatment earlier vs.
those with oldermothers. This was attributed to youngermothers
having less experience in taking care of children and therefore
being more likely to seek medical attention earlier (39).
Cancer-related factors such as the cancer type, symptoms,
stage, and tumor site/location also contribute to delays. Cancer
type was significantly associated with delayed time to diagnosis
especially when comparing different groups of cancers to
leukemia, an effect which persisted even after adjusting for
age, sex, and race (40). The timely diagnosis of cancer in
children was found to be further complicated by the rarity of
the disease and the non-specific presentation of symptoms as
well as misinterpretation of ambiguous cancer symptoms by
patients, parents, and physicians (18). Patients with abnormal
masses had shorter diagnosis delays, patients with rare symptoms
had shorter parent delay, fast-growing tumors had shorter delays
than slow-growing ones and patients who presented with pain
as the primary symptom had significantly longer total delay
and physician delay (35, 38). Patients with disseminated disease
also had significantly longer delays compared to patients with
localized disease (45).
The type of physician seen first (private vs. public), physician
specialty (pediatrician vs. family physician), type of facility
(private vs. public), health insurance, and the fear of visiting
tertiary health care institutions also contributed to delays among
children with suspected cancers (43). When the first health
consultant was a private physician, the lag time was shorter
than when it was a physician at a public clinic; and both lag
time and physician delay were shorter among children seen by
pediatricians compared to those seen by family physicians or
other specialists (44). Finally, a lack of health insurance combined
with the initial use of alternative medicine was also significantly
associated with longer patient delays (36).
This review could not identify studies that compared access to
oncological services between HIV-positive and negative children.
Yet, two U.S.-based studies focused on adults demonstrated
that people living with HIV were less likely to receive cancer
treatment and that the delay between diagnosis to treatment was
also significantly longer than that of HIV negative individuals
(41). The lack of resources and varying treatment availability
within and across different regions makes the evaluation of
cancer in the pediatric HIV population particularly challenging.
The weaknesses in health care infrastructure for diagnosing
cancers along with limited epidemiological expertise in LMICs,
especially in SSA also result in sparse data on the burden of AIDS
defining malignancies and other associated cancers (45).
Current Interventions and the Potential Role of
Socio-Economic Empowerment in Improving Access
Children with cancer in LMICs not only experience multiple
barriers to treatment access, but they also have lower childhood
cancer survival rates (15, 46). The reasons for the low survival
rates are multiple, interrelated, and associated with factors that
affect access to treatment services, treatment adherence as well as
abandonment. The small number of facilities providing cancer
treatment and supportive services along with lack of well-
trained multidisciplinary staff are further aggravated by poor
nutritional status of children and late patient presentation to the
health centers and/or specialized personnel (47). Hence, further
development and evaluation of interventions aimed at improving
access to oncological services for youth is required.
Despite improvement in outcomes for pediatric cancer
patients in LMICs, many challenges persist. Interventions
including targeted health education of guardians on the
importance of early care for children’s illnesses as well as
advocacy and education of health workers to facilitate the
identification of early warning signs of childhood cancer and
foster timely referral and diagnosis are crucial for patient
survival (40). Parent support groups also offer vital support
in providing medications, housing and psychosocial support
(48). Additionally, the establishment of cancer centers and
“twinning” partnerships with institutions from high-income
countries in many LMICs, especially in SSA countries, have led
to infrastructure improvement as well as personnel and facility-
capability to provide proper cancer treatment and care (47, 48).
Twinning partnerships occur across multiple levels including the
local public sector, private-sector and international organizations
and include education, care-linkage, mentorship (e.g., regular
online conferences in international partnerships), and in some
cases, funding (47).
Similarly, regional collaborations between cancer centers have
driven progress in pediatric access to treatment and survival (49).
Developing national protocols and guidelines for treatment that
account for local contexts (e.g., unavailability of certain drugs or
treatment modalities) is also another important step (47). For
instance, the committee for Pediatric Oncology in Developing
Countries published treatment guidelines for children with
common and curable cancers (including YLWHIV) (49, 50).
Other considerations include improving supportive care services,
infection control programs (especially opportunistic infections
among YLWHIV) and nutritional support benefits (47).
Developing sustainable and contextually relevant
interventions, especially in resource-poor settings is imperative.
While current interventions are vital and have resulted in
increased access and government involvement in oncological
care, socio-economic factors, and treatment-related costs play
a significant role in the cancer-care pathway (40). Hence,
interventions increasing the ability of families with young cancer
patients to engage with the healthcare system may lead to better
health outcomes.
This economic empowerment can be achieved using an asset-
based model, which is an integrated approach for building
human, social, and economic capital (51, 52). The asset theory
posits that asset building (e.g., savings, educational opportunities,
and economic opportunities in the form of small businesses or
income generating activities) has important long-term positive
benefits (53, 54). Asset theorists have described these as “asset
effects” (55) which include acquiring a sense of economic
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security, self-confidence, hope, and responsibility (56). This
empowerment could facilitate families’ access to formal financial
products (e.g., savings and credit lines) to meet the healthcare
needs such as treatment for HIV and cancer, foster adherence and
consequently improve health outcomes (57).
People living in poverty acquire personal financial resources
either through savings or loans (58). However, if the latter are
not managed well, they can increase the financial burden on
recipients rather than facilitate improved quality of life (59).
Therefore, saving programs would be the better option to address
disparities in treatment access and help families with children
suffering from cancer.
Asset-based development through savings interventions has
been used with success to improve quality of life. For example,
the Suubi projects (Hope in Luganda, the local language in the
region) in the Greater Masaka region in Uganda have employed
an asset development approach in working with orphaned
and vulnerable children in poverty -including YLWHIV, which
among other components, involve setting up a Child Savings
Account (CSA) (58, 59). CSA is a matched savings account
held in the child’s name in an officially registered financial
institution or bank (60) and for youth and their families to
use for school-related expenses, post-primary education, and in
the case of YLWHIV for medical expenses, or to start small
family business development projects (53, 60). Tested using
randomized controlled trials, results indicate that this program
is effective in reducing children’s economic barriers to attend
school, supporting the argument that such programs can address
family-level and child poverty, which could in turn improve
health outcomes. More specifically for YLWHIV, in a large
sample of Ugandan adolescents between the ages of 10 and
16 years and living with HIV, the intervention was found to
significantly improve viral suppression, the primary marker of
ART adherence (61, 62). It is possible that the promotion of
financial stability may have addressed transport costs and food
security, both of which are factors identified as barriers to ART
adherence (63–66). Given these results, economic empowerment
interventions may also effectively address barriers to cancer
treatment and care.
Next Steps
Capacity building activities across all levels of health care
systems are key to the care and treatment of children with
cancer in LMICs—both with and without HIV infection.
This approach requires collaborative work based on local
stakeholder and government buy-in in order to set the
priorities because they know best what they need and is
feasible. Strengthening and expanding comprehensive pediatric
cancer registries, especially in SSA will provide opportunities
for research and innovative treatment approaches to improve
survival. Collaboration between new and existing cancer and
HIV registries for children and youth can further facilitate this
process. Larger longitudinal studies are also needed to determine
incidence of cancers in HIV-positive and HIV-negative children
to better characterize the association between seropositivity
and cancer.
Established HIV-care systems and mechanisms at both local
and regional levels should be utilized to provide cancer diagnosis
and linkage to treatment services. Setting up centralized cancer
treatment centers, partnering with established cancer units,
establishing locally adapted protocols, and getting financial
support from the government are all helpful in reducing
treatment abandonment (41). Careful consultation is also
required between the different subspecialties involved in
the care of these children, including the multidisciplinary
HIV team, infectious disease, and oncology subspecialists,
so that decisions about cancer treatment are made in
the context of ART, and consider the treatment required
for other HIV-associated disorders and patient quality
of life. As cancer becomes more frequent in both people
living with HIV and YLWHIV, physicians need to better
understand and agree on when to treat, when to palliate,
and, with treatment, how to minimize complications while
achieving remission.
Research on diagnosis delays in childhood cancer is also
important. There is also a need for more studies to investigate the
potential impact of delays on prognosis outcomes. Future studies
should study access to oncological services among YLWHIV,
a high-risk group for pediatric cancer. Examining the impact
of patient and provider/healthcare-system delays on disease
severity and prognosis as well as the factors influencing these
delays would inform effective policies and programs aimed
at eliminating obstacles in the cancer-care pathway for youth
with cancer.
Finally, better strategies to reduce treatment abandonment
and improve survival in childhood cancer in the developing
world are still needed. Increasing awareness of childhood
cancers and addressing structural and socio-economic factors
impacting access to cancer treatment services can be considered
as potential strategies. Moreover, complementing current
structural interventions with the adoption of asset-based
models to improve access and adherence to oncological
treatment could be vital to pediatric cancer patients,
especially YLWHIV.
CONCLUSION
Pediatric cancers among youth are rare but serious life-
threatening conditions. YLWHIV are particularly at a
higher risk of developing and dying from cancer than their
general population counterparts. Pediatric cancer patients
have limited access to oncological services and health-
system-related factors play a major role in delayed access
to treatment. Failure to meet treatment costs is a major
contributor to treatment abandonment. This paper discussed
the potential role of socio-economic strengthening and provided
evidence that asset-building savings programs can increase
financial security and subsequently result in better health
outcomes. Further exploration, development, and evaluation
of interventions to address gaps and challenges to access to
oncological services among YLWHIV and all children are
crucial next steps.
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ABBREVIATIONS, ACRONYMS, AND
DEFINITIONS
Abbreviation/
Acronym
Definition
YLWHIV Youth living with HIV/AIDS. Youth are defined as individuals
between the ages of 0 and 24 years. Therefore, this definition
includes younger children 12 years and under, teenagers and
young adults (18–24)
LMICs Low- and middle-income countries as defined by the World
Bank
LIC Low-income countries as defined by the World Bank
WHO World Health Organization
ART Antiretroviral therapy
SSA Sub-Saharan Africa
HR Hazard ratio
CSA Child Savings Account
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